Previous 10 | Next 10 |
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Maire Osborn, Ph.D., Associate Director of Neuro Discovery at Dicerna...
– Webinar To Feature Therapeutic Expert Henry Kranzler, M.D. – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, t...
Dicerna Pharmaceuticals (DRNA) announces that its development partner Roche (RHHBY) has initiated RG6346 in a Roche-sponsored Phase 2 combination trial for the treatment of chronic hepatitis B virus ((HBV)) infection.RG6346 is an investigational GalXC RNAi therapeutic that Dicerna is dev...
– Phase 2 Initiation Triggers $25 Million Milestone to Dicerna – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics,...
Image source: The Motley Fool. Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) Q4 2020 Earnings Call Feb 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Dicerna Pharmaceuticals Inc (DRNA) Q4 2020 Earnings Call Transc...
Dicerna Pharmaceuticals, Inc. (DRNA) Q4 2020 Earnings Conference Call February 25, 2021 4:30 p.m. ET Company Participants Lauren Stival - Senior Director of IR Doug Fambrough - President and CEO Shreeram Aradhye - Chief Medical Officer Doug Pagan - CFO Jim Weissman - COO Rob Ciappenelli - Chi...
– 2020 Highlights Include: Enrollment Completion of Pivotal PHYOX™2 Trial of Nedosiran for Primary Hyperoxaluria; Positive RG6346 Phase 1 Data for HBV; Positive Nedosiran Multidose Data from PHYOX3 Trial; First IND From Lilly Collaboration – – Compa...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its financial results for the full year ende...
Dicerna has a huge pipeline of both internal and partnered RNAi products, one of which already has positive Phase 3 results. Dicerna has over $600 million in cash with more to come from its lucrative big pharma partnerships. Despite this, Dicerna trades at a huge valuation discoun...
– PHYOX4 Data Expected Mid-Year 2021 – – Planned Nedosiran New Drug Application (NDA) Submission On Track for Third Quarter of 2021 – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”)...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...